The Charles River FDA collaboration, announced on Oct. 22, 2026, brings together Charles River Laboratories International, Inc. (NYSE: CRL), the U.S. Food and Drug Administration (FDA) and Labcorp under a Research Collaboration Agreement (RCA). The stated aim is developing sensitive screening tools to quantify and rank the abuse potential of new drugs. The announcement was issued from Wilmington, Massachusetts, through Business Wire and posted on the company’s investor relations site.
According to the release, the Charles River FDA collaboration is intended to produce tools covering new drugs generally, including abuse-deterrent formulations (ADFs) and emerging drugs of abuse. The agreement establishes a joint research framework to enhance objective, standardized metrics for quantifying abuse potential in preclinical models, work that may inform regulatory assessments under the Controlled Substances Act (CSA). Charles River has also published its own explainer on how to measure abuse potential in new drugs.
Dr. Namandjé N. Bumpus, Chief Science and Innovation Officer at Charles River, said “Assessing abuse potential is essential for identifying risks” and added that the work will improve public health safeguards. She said the effort should amplify shared work to protect patients and communities. The Charles River FDA collaboration is therefore presented as a public health initiative as much as a scientific one.
Charles River FDA Collaboration: What the Research Agreement Covers
Under the RCA, the three organizations in the Charles River FDA collaboration will pursue a shared research effort rather than a commercial product launch. The release describes the goal as developing screening tools that can quantify and rank the abuse potential of new drugs. Financial terms, the agreement’s duration, the specific compounds to be studied and the individual responsibilities of each party were not disclosed in the announcement, and this article does not estimate them.
The release also positions the work within the regulatory landscape. Abuse potential assessments are described as vital components of the safety evaluation of central nervous system active compounds, and the release states that both the FDA and the Drug Enforcement Administration (DEA) rely on them for scheduling control measures. The Charles River FDA collaboration therefore touches an assessment step that sits close to final regulatory decisions, although the company did not say how or when any new method might be adopted.
Labcorp is named as the third party to the agreement, alongside the FDA and Charles River. The release does not describe Labcorp’s specific scientific contribution, so the details of its role should be treated as not disclosed. The stated focus on consistency across laboratories may explain why more than one laboratory participates, but that is an editorial observation and not a statement from the release.
| Agreement Element | Detail From the Release |
|---|---|
| Announcement date | Oct. 22, 2026 |
| Announcing company | Charles River Laboratories International, Inc. (NYSE: CRL) |
| Agreement type | Research Collaboration Agreement (RCA) |
| Parties | Charles River, the U.S. FDA and Labcorp |
| Objective | Develop sensitive screening tools to quantify and rank abuse potential of new drugs |
| Product types named | Abuse-deterrent formulations (ADFs) and emerging drugs of abuse |
| Regulatory context | Controlled Substances Act (CSA) assessments |
| Financial terms | Not disclosed |
| Duration | Not disclosed |
| Specific compounds | Not disclosed |
Why the Charles River FDA Collaboration Matters for Abuse Potential Assessment
The release frames the project as advancing regulatory science. It states that enhancing objective, reproducible methods supports evidence based decision making, and that the collaboration will help evaluate approaches that could improve the consistency and sensitivity of abuse potential assessments. In practical terms, the Charles River FDA collaboration is built around the idea that standardized metrics could make results easier to compare across studies and sites.
Two categories of products are specifically named as targets for better tools: abuse-deterrent formulations and emerging drugs of abuse. The release does not name any individual drug candidate, sponsor or marketed product, and none are referenced here.
The stated public health aim of the Charles River FDA collaboration is to assess the abuse potential of new drugs more reliably and effectively by improving sensitivity, accuracy and consistency across laboratories. For drug developers who commission preclinical safety work, the announcement signals ongoing effort on the methods that underpin such assessments. The release makes no claim about changes to current FDA or DEA requirements.
| Regulatory Topic | What the Release States |
|---|---|
| Assessment type | Abuse potential assessment |
| Compounds affected | Central nervous system active compounds |
| Agencies relying on assessments | FDA and Drug Enforcement Administration (DEA) |
| Use of assessments | Scheduling control measures |
| Legal framework referenced | Controlled Substances Act (CSA) |
| Stated improvement targets | Sensitivity, accuracy and consistency across laboratories |
| Changes to FDA or DEA requirements | Not stated |
How the Charles River FDA Collaboration Uses Behavioral Economics
Charles River will leverage behavioral economic models of supply and demand to analyze self administration data, according to the release. These models assess the relative reinforcing properties of substances, which helps researchers evaluate abuse potential and compare it with that of known drugs of abuse. This is the contribution the company highlights for its part in the Charles River FDA collaboration.
The company reports that a recent behavioral economics pilot at its Mattawan site produced preliminary proof of concept data demonstrating the promise of this approach. The release does not publish the pilot’s design, sample size, compounds tested or results, so those details are listed as not disclosed. Because the data are described as preliminary, the approach should be read as promising but not yet validated, which is the gap the agreement is meant to address.
Charles River also points to its track record. The company states it has conducted over 100 abuse potential studies and contributed to assessments of the abuse potential of 15 FDAapproved products. That experience is the main credential cited for its role, and it is a company reported figure that the release does not break down by year or compound class.
| Charles River Capability | Detail From the Release |
|---|---|
| Abuse potential studies conducted | Over 100 |
| FDA approved products with Charles River contributions | 15 |
| Analytical approach | Behavioral economic models of supply and demand |
| Data analyzed | Self administration data |
| What the models assess | Relative reinforcing properties of substances |
| Pilot location | Mattawan site |
| Pilot outcome | Preliminary proof of concept data |
| Pilot design and results | Not disclosed |
Charles River FDA Collaboration: Company Background and Outlook
Charles River Laboratories International, Inc. trades on the NYSE under the ticker CRL. In its standard company description, it says it provides essential products and services to pharmaceutical and biotechnology companies, government agencies and leading academic institutions worldwide. Its stated focus spans discovery, early stage development and safe manufacture of new therapies. More detail on its portfolio is available on the company website, and investor materials, including SEC filings, are hosted on its investor relations site.
Investors and industry readers should note what the release does not say. No revenue impact, funding amount, timeline or commercial milestone is attached to the agreement, and the release contains no financial guidance. Any assumption about financial effect would be speculation, so this report limits itself to the facts the company has published about the Charles River FDA collaboration.
Media and investor inquiries are routed through named contacts in the release: Todd Spencer, Corporate Vice President, Investor Relations, for investors, and Amy Cianciaruso, Corporate Senior Vice President and Chief Communications Officer, for media.
In summary, the Charles River FDA collaboration is a research stage agreement focused on better abuse potential tools, with the scientific approach described but the commercial and timeline details left undisclosed. Further developments in the Charles River FDA collaboration, if any, would need to come from the companies or the agencies themselves.
